Eligible Companies for Exchange

A2 Bio is the developer of a cell therapy aimed at curing cancer through precise tumor targeting. The company creates engineered tumor cells that focus on the genetic material deficiencies in tumors, selectively destroying tumor cells while sparing normal ones. This innovative approach allows physicians to transform the treatment of solid tumors.

Aardvark Therapeutics is focused on developing small molecule therapeutics aimed at treating obesity and rare genetic metabolic disorders. Their innovative therapeutics provide a pioneering oral formulation that precisely disrupts hunger signaling while maintaining energy balance, without affecting nutrient absorption. This approach equips healthcare providers with a safe and efficacious treatment option for diseases associated with obesity.

AcuityMD develops a software platform for medical technology, aimed at enhancing the design and marketing of medical devices. The platform integrates strategic insights and market data into a collaborative tool that can be utilized across different departments, allowing medical companies to foster stronger connections with the physicians they support.

Alamar Biosciences has developed a cutting-edge precision proteomics platform aimed at protein analysis and cancer detection. This platform specializes in innovative antibody technologies crucial for diagnosing diseases such as cancer, and it supports the discovery of new biomarkers for early disease detection and prevention. By doing so, Alamar Biosciences enables healthcare providers to identify and potentially treat patients at an early stage, offering hope for early intervention in common diseases.

Alterome Therapeutics specializes in precision oncology treatments aimed at targeting oncogenic drivers. The company's approach leverages structure-guided drug discovery and sophisticated computational chemistry to create alteration-specific small molecule therapies. This enables the healthcare industry to address cancer targets with novel, selective treatments that enhance patient outcomes and increase survival rates.

Arbor Biotechnologies develops genomic tools aimed at enhancing human health and promoting sustainability. The company's technology leverages AI and machine learning to compile genomic sequence data, optimizing future cycles of treatments for genetic diseases previously deemed incurable. This enables drug developers to perform whole-gene replacements and accurately correct mutations, facilitating treatment for all patients with genetic disorders.

Attralus is engaged in creating immunotherapies and an imaging diagnostic platform aimed at treating multiple systemic amyloid diseases. The company's focus is on developing treatments to eliminate amyloid fibrils in patients suffering from systemic amyloid conditions such as light chain, transthyretin, and LECT2 amyloidosis. This enables the healthcare sector to provide more effective treatments for amyloidosis patients.

Be Biopharma is pioneering B cell medicines designed for applications extending beyond mere cytotoxicity. The company's therapies tackle significant challenges in cell and gene treatments, offering solutions that are durable, reprogrammable, and administrable without harmful conditioning. This innovation empowers healthcare professionals to address diseases such as cancer, autoimmune disorders, and enzyme deficiencies effectively.

Bluejay Therapeutics develops therapeutic medicines aimed at providing curative treatments for serious viral and liver diseases. The company's approach targets the reduction of viral surface antigen monoclonal antibodies to restore adaptive immunity, with an initial focus on chronic hepatitis B (CHB) and chronic hepatitis D (CHD). This enables patients to enhance their immunity and recover from infections.

Brightside Health operates as a healthcare company dedicated to reducing anxiety and depression. Their platform emphasizes depression evaluation, treatment, and monitoring using clinically validated assessments and insights. It offers lifestyle tools, resources, medication, therapy referrals, and progress tracking, allowing patients to access quality depression care. This empowers them to maintain healthy, balanced, and productive lives.

Capstan Therapeutics aims to enhance the potential of in vivo RNA-based therapies by utilizing its proprietary targeted delivery systems. The company employs targeted lipid nanoparticles to facilitate off-the-shelf immunotherapies, ensuring precise control over the dosage and activity of engineered cells. This approach allows researchers to develop groundbreaking products for treating oncology, fibrosis, and inflammation-related diseases.

Carrum Health operates an online healthcare platform designed to assist employers in offering top-tier healthcare benefits to their workforce. This platform connects forward-thinking, self-insured employers with regional healthcare providers using a comprehensive bundled payment system. This model helps patients lower their healthcare expenses, often resulting in little to no out-of-pocket costs.

Casana develops in-home health monitoring technologies designed to empower practitioners in managing patients' cardiac health from home. Casana's device passively collects health parameters and analyzes them within context, aiming to deliver unique insights into health and trends over time. This enables caregivers to access reliable and consistent vital signs information, ultimately improving the lives of individuals.

Cellanome has developed a distinctive multi-omics platform aimed at analyzing biology with unmatched detail and scale. The company's platform is adept in genome sequencing, microfluidics, and integrated sensors, along with expertise in molecular biology and biochemistry. This empowers scientists to create innovative solutions for intricate biological challenges.

Centivo offers self-funded health plans designed to make healthcare more affordable for both employees and employers. The company allows employers to provide their workforce with user-friendly, cost-effective, and predictable healthcare options. Centivo enhances the member experience by providing a variety of benefit choices, including proprietary primary care-centered models and traditional networks. This enables self-funded employers to support the sustainable livelihoods of their employees.

Chroma Medicine is advancing genomic medicines aimed at transforming the treatment of genetically influenced diseases. The company's innovative approach leverages epigenetics, the natural mechanism for regulating genes, by employing programmable epigenetic editors. These editors specifically target genes and manage chromatin structure by pairing a DNA binding domain with epigenetic effector domains. This enables healthcare professionals to utilize a new class of therapeutics, achieving unprecedented precision in controlling gene expression.

Conformal has developed a medical implant device aimed at preventing strokes in patients with atrial fibrillation. This innovative device is specifically designed for non-valvular atrial fibrillation and adapts to the unique anatomy of each patient, ensuring effective atrial appendage closure. By providing this tailored solution, Conformal enables doctors and medical professionals to effectively treat patients at risk of strokes, ultimately saving lives.

Convergent Therapeutics is a clinical-stage biotechnology company committed to harnessing the full potential of dual-targeted combination strategies for cancer treatment. The company has created a therapeutic platform that targets both validated and novel cancer antigens by utilizing targeting agents with varied bio-distributions, such as monoclonal antibodies, ligands, and supra-additive therapeutic doses. This approach enables healthcare providers to deliver effective cancer therapies to their patients.

Covera Health is the developer of a clinical intelligence platform designed to minimize medical misdiagnoses and enhance care quality. The company's solutions scrutinize clinical datasets to promote emerging science, focusing initially on radiology—where accurate and early diagnosis significantly influences a patient's care journey. By employing clinically validated, science-based tools, it aids physicians in improving their care, ensuring correct diagnoses for patients, and enabling the healthcare system to support quality enhancement on a large scale. This approach allows employers and payers to boost patient outcomes while reducing unnecessary healthcare expenditures.

Detect develops an AI platform aimed at discovering biotechnology tools. This platform features an intelligent evolution engine that enhances molecular designs through AI and selects top performers using unique, parallel single-molecule technologies. Detect's innovation assists the biotechnology industry in creating the next generation of biosensors, gene-editing tools, and biomaterials.

Dewpoint Therapeutics is developing a healthcare technology aimed at identifying new drugs for a wide range of diseases. By leveraging a proprietary experimental and AI-powered platform, the company enhances drug discovery. Dewpoint Therapeutics utilizes machine-learning-based image analysis tools to visualize condensates and offers an engine comprising a collection of engineered cell lines with trackable condensates to prevent detrimental protein sequestration. The company has active programs in oncology, neurodegenerative, cardiopulmonary, and metabolic diseases, and collaborates with leading academic and pharmaceutical partners globally. This enables healthcare providers to access new therapies that address unmet medical

Dispatch Biotherapeutics is focused on creating cancer treatments that leverage the power of the immune system. The company is dedicated to developing therapies aimed at eradicating cancer tumors while preventing their recurrence, thereby offering patients more effective cancer treatment options.

Egenesis is developing a gene editing and genome engineering platform aimed at revolutionizing solid organ and therapeutic cell transplantation for treating life-threatening illnesses. The company's platform provides gene editing techniques to create human-compatible organ tissue cells and spearheads programs in kidney and islet cell transplantation, allowing patients to recover and maintain a healthy life.

Elektrofi has developed a drug delivery platform aimed at enhancing subcutaneous administration. Their formulation system efficiently processes a wide range of therapeutic molecules, and their technology is capable of handling large, complex, and delicate proteins, such as monoclonal antibodies, as well as bispecific and fusion proteins. This enables drug manufacturers to create groundbreaking therapies with ease, empowering patients to have control over how they receive and benefit from transformative medicines.

Engrail Therapeutics develops transformative medicines aimed at alleviating the significant impact of nervous system diseases. The company's solutions focus on improving the lives of patients with life-limiting neurological conditions by merging biological insights with effective clinical solutions. Engrail Therapeutics is committed to creating and advancing a diverse portfolio of groundbreaking treatments, simplifying complex disease therapies, and ultimately helping patients lessen their overall disease burden.

Equip operates a virtual eating disorder treatment program designed to help families recover from eating disorders in the comfort of their homes. The program provides a dedicated team, including a therapist, dietitian, medical doctor, peer mentor, and family mentor, who work together to support meeting eating goals. This approach allows patients to achieve recovery affordably at home.

Firefly Health offers primary health care services designed to transform patient care and ensure it is accessible to everyone. By integrating technology with a dedicated care team, the company provides continuous, insightful care that encourages behavioral changes and delivers value. Firefly Health's virtual-first approach to primary care includes live video appointments with primary care physicians and a team dedicated to convenience, all without any membership fees. This enables customers to make informed health decisions while assisting clinicians in delivering consistent and proactive care.

Flare Therapeutics is a health-tech company focused on developing small-molecule precision medicines for cancer patients. Their platform is adept at targeting transcription factors to identify precision treatments for neurology, rare genetic disorders, immunology, and inflammation. This enables healthcare professionals to alter the course of disease treatment effectively.

Florence offers an electronic document workflow software aimed at simplifying and ensuring compliance for clinical trial documents. Their platform minimizes repetitive tasks for trial sites and automates site access, facilitating remote document monitoring. Additionally, it provides real-time insights into study progress, allowing clients to streamline trial operations and expedite research studies.

FogPharma specializes in creating cell-penetrating mini proteins (CPMPs) aimed at targeting and neutralizing cancer-causing proteins within cancer cells. These CPMPs represent a groundbreaking class of medicines capable of reaching drug targets that conventional therapies cannot address, allowing physicians to effectively treat diseases related to cancer.

Foresight Mental Health operates a clinic focused on mental health and wellness, providing diverse treatments and healthcare services. By transforming mental healthcare through its clinic network, the company provides patient profiles, a repository of scientific research, and analysis of crucial data including genetic profiles, detailed symptom assessments, and brain-chemical balance estimates, helping patients achieve greater happiness and health.

Frontier Medicines has developed a chemoproteomics platform aimed at speeding up the creation of new drugs. This platform combines computational techniques with machine learning to identify and target novel binding sites on proteins, making these sites accessible for small-molecule drug discovery and development. This innovation allows healthcare professionals to offer medications that can alter the trajectory of debilitating diseases, ultimately benefiting patients.

Genesis Therapeutics is a developer of a computational platform focused on discovering small-molecule drugs. The company utilizes its proprietary molecular AI technology to advance the discovery and development of innovative drugs aimed at treating patients with severe and debilitating diseases. This approach empowers the medical community to enhance and optimize clinical outcomes for patients.

Graviton BioScience is a developer of clinical-stage drugs aimed at treating autoimmune disorders, cancer, and other severe diseases. The company's platform is focused on designing and advancing therapeutics for CNS, autoimmune, fibrotic, and various serious conditions where ROCK2 and its other compounds are crucial in disease pathology. Graviton BioScience offers drug candidates targeting Rho-associated protein kinase, a significant mediator of cellular contractility and fibrosis. This enables customers to potentially access revolutionary treatments for a variety of debilitating illnesses.

Hexagon Bio has developed a synthetic biology platform that leverages data science to explore genomes for small molecule inhibitors targeting specific proteins. This platform integrates genomics, synthetic biology, and automation to uncover evolutionarily refined compounds and their protein targets directly from fungal genomes. By tapping into the global metagenome, Hexagon Bio aims to identify new medicinal compounds, facilitating the development of innovative treatments to enhance patient care.

Iambic Therapeutics has developed a cutting-edge quantum molecular simulation engine focused on expediting the discovery of new therapeutics. This innovative engine integrates AI-driven technology with automated synthesis processes to swiftly design small-molecule drugs. This enables healthcare professionals to achieve molecular predictions with significantly enhanced accuracy, transforming the landscape of drug discovery.

IDRx specializes in developing oncology-focused precision therapies aimed at transforming cancer treatment. The company creates precision combination therapies, featuring highly selective, engineered drug combinations that target key tumor escape mechanisms to extend therapeutic responses. This approach empowers healthcare professionals to create effective cancer treatments through purposefully crafted combinations, offering tailored cancer medicines for patients.

Inceptive is a developer of a biological software development platform focused on creating synthetic molecules for intricate biological functions. The company innovates new medicines and biotechnologies, allowing clients to achieve healthcare and biotech advancements that were once out of reach.

Infinitus Systems has developed a healthcare AI communication tool that streamlines communication by automating tedious and time-consuming phone calls with precision and easily trackable updates. The tool allows users to effortlessly submit call requests to the system, which then queues the tasks. Users are promptly notified upon task completion and can also choose to collect results in bulk at their convenience.

KSQ develops transformative medicines designed to accurately target the key nodes of disease. The company's industrialized functional genomics engine employs a range of tools to identify novel pathways and targets in oncology and immuno-oncology. This enables doctors to discover new drug targets, understand mechanisms of drug efficacy, and identify transformative single-agent and combination therapies to benefit patients.

Levels has developed a wellness wearable designed to monitor metabolic fitness. This device offers real-time data, delivering immediate feedback on individual metabolism. It helps users quickly comprehend how their bodies react to dietary and lifestyle choices, empowering them to optimize their diets and routines to achieve personal goals.

LifeMine is the developer of a drug discovery platform designed to unravel human biology and craft advanced therapeutics targeting the core drivers of serious human diseases. Leveraging fungal biodiversity, the company's platform develops therapeutics that are both mechanistically and structurally novel, addressing previously insurmountable therapeutic challenges. By doing so, LifeMine enables healthcare providers to tackle difficult human diseases through innovative biological mechanisms.

LightForce has developed a customized three-dimensional printed orthodontic bracket system aimed at providing patient-specific digital dental treatment. Their product utilizes on-demand three-dimensional manufacturing to offer tailored treatment plans, representing a significant advancement in bracket-based treatment protocols. This innovation allows orthodontists to achieve unprecedented control, effectively addressing challenging clinical situations and improving treatment efficiency.

Loyal specializes in creating veterinary medications designed to enhance the health span and lifespan of dogs. The company's products aim to postpone the development of age-associated diseases such as cancer, heart disorders, and metabolic conditions, allowing dogs to enjoy longer and healthier lives.

Luna Physical Therapy operates a health and wellness center focused on delivering physical therapies. The company excels in offering treatments for orthopedic and sports-related injuries, senior care, post-surgical rehabilitation, and addressing back and neck pain. Additionally, they provide specialty care and targeted training, allowing patients better access to treatment. Therapists enjoy the independence and flexibility necessary to advance their careers and succeed in their practice.

Lycia Therapeutics is a biotechnology firm focused on discovering and developing innovative therapeutics. Utilizing its lysosomal targeting chimeras platform, the company aims to create treatments that degrade extracellular and membrane-bound proteins responsible for various challenging diseases, such as cancers and autoimmune disorders. This approach assists medical professionals in accessing drugs designed to treat and potentially cure these conditions.

Marea is a biotechnology company focused on cardiometabolic diseases. Its primary initiative, MAR001, is currently in Phase 2 of clinical development. Marea is dedicated to creating innovative treatments for individuals at risk of heart attacks, aiming to address elevated remnant cholesterol and metabolic dysfunction.

Medallion offers a licensing and credentialing platform tailored to streamline the paperwork demands of the healthcare sector. This platform features facilities for new licensing and renewals, complete with primary source verification, tracking of continuing medical education, document management, and payer enrollment. It aids healthcare providers and telemedicine companies in minimizing time spent on administrative tasks, allowing them to dedicate more time to patient care.